Cargando…

Correction: Potential Formula for the Calculation of Starting and Incremental Insulin Glargine Doses: ALOHA Subanalysis

Mostrar otras versiones (1)

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4103854/ http://dx.doi.org/10.1371/journal.pone.0103390

Ejemplares similares

Correction: Potential Formula for the Calculation of Starting and Incremental Insulin Glargine Doses: ALOHA Subanalysis
Publicado: (2014)

Potential Formula for the Calculation of Starting and Incremental Insulin Glargine Doses: ALOHA Subanalysis
por: Kadowaki, Takashi, et al.
Publicado: (2012)

Analytical Model of ALOHA and Time- and Frequency-Asynchronous ALOHA with Forward Error Correction for IoT Systems
por: Clazzer, Federico, et al.
Publicado: (2022)

Correction to: MYL1501D Insulin Glargine: A Review in Diabetes Mellitus
por: Hoy, Sheridan M.
Publicado: (2020)

Correction to: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis
por: Mansell, Kerry, et al.
Publicado: (2019)

Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine
por: Handelsman, Yehuda, et al.
Publicado: (2019)

Incidence and predictors of hypoglycemia in Japanese patients with type 2 diabetes treated by insulin glargine and oral antidiabetic drugs in real-life: ALOHA post-marketing surveillance study sub-analysis
por: Odawara, Masato, et al.
Publicado: (2014)

Improved Treatment Satisfaction and Self-reported Health Status after Introduction of Basal-Supported Oral Therapy Using Insulin Glargine in Patients with Type 2 Diabetes: Sub-Analysis of ALOHA2 Study
por: Tsukube, Shoko, et al.
Publicado: (2015)

Insulin glargine overdose
por: Doğan, Fatma Sarı, et al.
Publicado: (2012)

Dose-Response Effects of Insulin Glargine in Type 2 Diabetes
por: Wang, Zhihui, et al.
Publicado: (2010)

Glargine and degludec: Solution behaviour of higher dose synthetic insulins
por: Adams, Gary G., et al.
Publicado: (2017)

Correction: A Fast Incremental Gaussian Mixture Model
por: Pinto, Rafael Coimbra, et al.
Publicado: (2015)

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus
por: Linnebjerg, Helle, et al.
Publicado: (2016)

Slotted ALOHA on LoRaWAN-Design, Analysis, and Deployment
por: Polonelli, Tommaso, et al.
Publicado: (2019)

Optimizing the Performance of Pure ALOHA for LoRa-Based ESL
por: Khan, Malak Abid Ali, et al.
Publicado: (2021)

Aloha - Optics studies by combined kick-response and dispersion fits.
por: Fuchsberger, K
Publicado: (2009)

Insulin glargine and the risk of cancer
por: Ahmed, FA
Publicado: (2010)

Correction to: Window dressing: possibilities and limitations of incremental changes in solitary confinement
por: Augustine, Dallas, et al.
Publicado: (2021)

Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment
por: Oddone, Francesco, et al.
Publicado: (2022)

Correction to: Impact of Complete Revascularization on Development of Heart Failure in Patients With Acute Coronary Syndrome and Multivessel Disease: A Subanalysis of the CORALYS Registry
Publicado: (2023)

Correction: An Empirical Biomarker-Based Calculator for Cystic Index in a Model of Autosomal Recessive Polycystic Kidney Disease—The Nieto-Narayan Formula
Publicado: (2016)

Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
por: Tarigan, Tri Juli Edi, et al.
Publicado: (2021)

Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients
por: Jakobsen, Marie, et al.
Publicado: (2012)

Enigmatic relationship between chlorophyll a concentrations and photosynthetic rates at Station ALOHA
por: Laws, E.A., et al.
Publicado: (2016)

Correction: STOPP/START criteria for potentially inappropriate prescribing in older people: version 3
por: O’Mahony, Denis, et al.
Publicado: (2023)

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
por: Steinstraesser, A, et al.
Publicado: (2014)

How much is too much? Outcomes in patients using high‐dose insulin glargine
por: Reid, T., et al.
Publicado: (2015)

Fasting plasma glucose level-based formula for estimating starting daily dose in basal-bolus insulin therapy
por: Nagao, Mototsugu, et al.
Publicado: (2023)

A case of hypersensitivity to soluble and isophane insulins but not to insulin glargine
por: Belhekar, Mahesh N., et al.
Publicado: (2015)

Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial
por: Blonde, Lawrence, et al.
Publicado: (2019)

Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine
por: Hadjiyianni, I., et al.
Publicado: (2016)

Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus
por: Wang, Weimin, et al.
Publicado: (2022)

Experimental Energy Consumption of Frame Slotted ALOHA and Distributed Queuing for Data Collection Scenarios
por: Tuset-Peiro, Pere, et al.
Publicado: (2014)

Aloha Undergraduates: Development and Application of Local & Indigenous Topics into an Undergraduate Public Health Curriculum
por: Nelson-Hurwitz, Denise C., et al.
Publicado: (2019)

Direct-to-Satellite IoT Slotted Aloha Systems with Multiple Satellites and Unequal Erasure Probabilities
por: Tondo, Felipe Augusto, et al.
Publicado: (2021)

Single‐dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK‐1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects
por: Crutchlow, Michael F., et al.
Publicado: (2017)

Australian Workshops on Patients’ Perspectives on Hemodialysis and Incremental Start
por: Hegerty, Katharine, et al.
Publicado: (2022)

Incremental peritoneal dialysis after unplanned start initiation
por: Calice-Silva, Viviane, et al.
Publicado: (2022)

Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study
por: Cheng, Alice, et al.
Publicado: (2019)

Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus
por: Ilag, L. L., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_pd61669inql0tfq8bomnri3agk